Dr. Anna Farago, oncologist form the Massachusetts General Hospital, will explain in an oral presentation what kind of molecule lurbinectedin is, how it works, and what results were obtained from the phase I/II clinical study in combination with doxorubicin for the treatment of small-cell lung cancer, that led to the of the pivotal phase III ATLANTIS study, which is nearing completion. Dr. Farago is the lead investigator of this clinical trial. The presentation will take place on Wednesday the 21st of February at 11:50 a.m. (PT).
Lurbinectedin is currently under clinical investigation for different types of solid tumors such as small-cell lung cancer. When combined with doxorubicin, lurbinectedin reached a progression free survival of 5.3 months which compares favorably with historical data of topotecan as a single agent (the PFS varies between 3.1 and 3.5 months), This PFS increases up to 6.2 months in platinum sensitive patients. The data has shown so far that lurbinectedin does not produce mucositis, neuropathy or alopecia.
"In such a difficult disease setting with so few therapeutic options, lurbinectedin has shown encouraging data so far in terms of efficacy and tolerability. As the ATLANTIS phase III nears enrollment completion around mid-year, there is growing anticipation to see if the phase III data will offer these patients in this setting the first new therapeutic option since over twenty years ago", Dr Farago said.
With regards to the mechanism of action, this molecule is an inhibitor of the RNA polymerase II, which is essential for the activated transcription process. Through the inhibition of this transcription process, the compound is able to reduce the expression of different factors that are involved in the growth of the tumor.
The phase III ATLANTIS clinical study for small-cell lung cancer has already recruited more than two thirds of patients in more than 154 centers involved across 20 countries and with. For more information: https:/
About small cell lung cancer
SCLC is a very aggressive cancer that usually presents with distant metastases and has already spread at the time of diagnosis, thus limiting the role of traditional approaches and posing a worse prognosis compared to other lung cancer types. The 5-year survival rate is about 5% . About 18% of all the lung cancer cases diagnosed are SCLC, and only in the US more than 34,000 new cases are recorded every year. This tumor is strongly associated with tobacco smoking, posing an important public health problem . After failure to treatment with a platinum-based therapy in first line, the therapeutic alternatives are very limited, and the approval of the last drug for this disease took place 20 years ago.
Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.